Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00906321 · ClinicalTrials.gov registry record · NA

Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk

A NA study of Risk Reduction Behavior and High Risk for Breast Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
NA
Development phase
64
Enrollment target
1
Study location

NCT00906321 is a NA study of Risk Reduction Behavior and High Risk for Breast Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 64 participants, below the 5,918-participant average among 9 other Risk Reduction Behavior trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00906321, a NA study of Risk Reduction Behavior and High Risk for Breast Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
NA
Development phase
64 participants
Enrollment target
1
Study location

Study Summary

Background: * Chemoprevention is the use of preventive medications to reduce the risk of breast cancer for women who are at a high risk of developing the disease. Although the treatment has shown effectiveness in preventing cancer development, chemoprevention is notably underutilized even by women who are at a high risk of developing breast cancer. * Researchers are interested in determining if better decision support mechanisms, such as interactive Web sites, can help to overcome some of the barriers to chemoprevention. Objectives: \- To develop and test a prototype Web-based module that will provide decision support to women who are considering chemoprevention for breast cancer. Eligibility: * Women 35 years of age and older who are at high risk for breast cancer and whose doctor has recommended chemoprevention (either Tamoxifen or Raloxifene), and who have no other history of cancer (apart from non-melanoma skin cancer or precancerous cervical lesions). * Participants must have a working e-mail address and access to a computer with internet access and a telephone. Design: * Participants who are considering chemoprevention will be randomized to a Web-based decision support module or standard care online information resources. * Participation lasts two months and involves using the online resources provided and filling out questionnaires two times during the study (at the beginning and the end). The first time will be at the begin of the study. * No medical treatments are offered as a part of this study

Interventions

  • BEHAVIORAL Web-Based Decision Support

Study Locations (1)

Maryland

  • National Cancer Institute (NCI), 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2009-05-18
Est. Completion 2010-05-26
Phase NA

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00906321

The ClinicalTrials.gov registry entry for NCT00906321 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,918-participant average among 9 other Risk Reduction Behavior trials with a reported enrollment target (99% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Risk Reduction Behavior appearing as the primary indexed condition, and to 1 intervention - of which Web-Based Decision Support is the first listed.

NCT00906321 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00906321 about?

NCT00906321 is a clinical study titled "Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk". Background: * Chemoprevention is the use of preventive medications to reduce the risk of breast cancer for women who are at a high risk of developing the disease. Although the treatment has shown effectiveness in preventing cancer development, chemoprevention is notably underutilized even by women ...

What is the current status of trial NCT00906321?

This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2009-05-18. Estimated completion is 2010-05-26.

What conditions does trial NCT00906321 study?

This clinical trial studies the following conditions: Risk Reduction Behavior, High Risk for Breast Cancer.

What interventions are being tested in trial NCT00906321?

The interventions under investigation include: Web-Based Decision Support (BEHAVIORAL).

Who is sponsoring clinical trial NCT00906321?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00906321 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Risk Reduction Behavior

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.